微创Nuss手术治疗儿童漏斗胸的研究进展

漏斗胸是一种胸壁凹陷性畸形,Nuss手术是治疗漏斗胸的一种微创手术,具有创伤小、操作简便、并发症少、手术效果良好等优点,已成为治疗漏斗胸的首选术式。随着Nuss手术的不断改良以及腔镜技术的提高,Nuss手术的适用范围不断扩大,胸腔镜辅助Nuss手术在临床应用广泛。作者在Pubmed、万方数据、中国知网等数据库,以漏斗胸、Nuss手术、手术治疗为关键词,查阅相关文献,将微创Nuss手术治疗漏斗胸的概况、技术要点、争议及改良方法等作一综述。虽然Nuss手术的发展给漏斗胸患儿带来福音,但其临床应用的具体问题和中远期疗效仍需进一步研究。     

前置血管围产结局130例分析

目的:探讨前置血管临床特点、孕期管理及围产儿结局。方法:回顾性分析2013年1月至2019年5月在四川大学华西第二医院分娩的130例前置血管患者临床资料,分析其临床高危因素、孕期管理及围产儿结局。结果:130例前置血管患者占我院同期分娩产妇的1.86‰。108例(83.1%)单胎,22例(16.9%)多胎,自然受孕109例(83.8%),辅助受孕21例(16.2%),其中妊娠合并帆状胎盘(68.5%)和前置胎盘(33.8%)占多数,96.2%产前诊断前置血管的患者合并至少一个高危因素。产前诊断111例,70.3%中孕期诊断,29.7%晚孕期诊断,诊断后行严密监测,入院孕周(33.7±2.2周),分娩孕周为35.0±1.6周,34~37周分娩77例。130例分娩活产儿150个,活产儿中存活145个,其出生体质量为2422.8±462.5 g,74例(51.0%)转NICU,在NICU住院时间为8(1~49)天。产前诊断组中,多胎妊娠病例的入院孕周、分娩孕周较单胎早,早产率和新生儿死亡率明显高于单胎妊娠病例(P<0.05)。产前诊断组与产时产后诊断组新生儿早产率为87.8%与55.6%(P<0.05),新生儿死亡率分别为2.4%和7.4%(P=0.220)。结论:规范产前检查、早期诊断、严密监护胎儿情况并适时终止妊娠有助于改善前置血管孕妇围产儿结局。     

Trial of Labor After Cesarean in Adolescents – A Multicenter Study

Study ObjectiveData regarding trial of labor after cesarean delivery (TOLAC) among young women are limited. The aim of this study was to assess the TOLAC success rate and its related factors among adolescent women who had never delivered vaginally.DesignA multicenter retrospective cohort study of all adolescent women aged ≤21 years with a history of 1 previous cesarean delivery, who delivered in 2 tertiary medical centers during 2007-2019. Women were allocated to 2 groups: 1) women who underwent TOLAC, and 2) women who had a repeat cesarean delivery with no trial of labor. Maternal and neonatal outcomes were compared between the two groups. In addition, perinatal outcomes were compared between women with successful and unsuccessful TOLAC.ResultsThe study cohort included 167 women who had a previous caesarean delivery; 117 underwent TOLAC and 50 underwent a repeat cesarean delivery with no trial of labor. Neonatal birthweight (median 2937 vs 3170 g, P = .03) and gestational age at delivery (median 38 weeks vs 39, P = .009) were lower in the repeat cesarean group as compared to those undergoing TOLAC. Overall, 97 of 117 participants (83%) had a successful TOLAC. Failed TOLAC was associated low birthweight as compared to successful TOLAC (5 [25%] vs 7 [7%], odds ratio [OR] 4.3, 95% confidence interval [CI] 1.2-15.3, P = .02), and birthweight difference between current and previous deliveries was higher in the failed TOLAC group (median 315 vs 197 g, P = .04). Rates of neonatal Apgar score at 1 minute < 7 and of neonatal intensive care unit admission were higher in the TOLAC failure group (4 [20%] vs 5 [5%], OR 4.6, 95% CI 1.1-19.0, P = .03, and 4 [20%] vs 4 [4%], OR 5.8, 95% CI 1.3-25.6, P = .02), respectively). In a multivariable logistic regression analysis, only low birthweight was independently associated with TOLAC failure (adjusted OR 9.9, 95% CI 2.1-45.4, P = .003). Two cases of uterine rupture occurred in the no trial of labor group, whereas none were encountered in participants undergoing TOLAC.ConclusionsTOLAC in adolescent women who had never delivered vaginally is associated with a relatively high success rate.     

Patients can accurately self-report their elbow range of motion following surgery for trauma

IntroductionThere is an increased demand of telemedicine in the recent century, especially with the outbreak of Covid-19. The aim of this study was to investigate patients' reliability in self-assessing own elbow range of motion following surgery for trauma.MethodsAll patients of age ≥16 years who underwent surgery for elbow trauma at the local trauma unit between March 2015 to Aug 2018 were reviewed retrospectively. Identified cohort was invited to self-assess their elbow range of motion (ROM) using questionnaire with image instruction. They were then followed up with a clinical review for objective measurements by the lead clinician. Independent T-test was used to compare the measurements between patients and clinician. The power of the study was calculated using G1Power software.ResultsThirty-five patients were enrolled in the study with mean age of 41 years. 11 of 35 patients had an associated elbow fracture dislocation associated. Mean patient reported total ROM was 105.7° ± 32.8°, with mean extension of 24.6° ± 18.9° to mean flexion of 130.3° ± 18.2°. Mean objective ROM measured by lead clinician was 112.6° ± 18.3°, with mean extension 22.4° ± 10.9° to mean flexion 135.0° ± 10.8°. No statistical significance was found between self-reported and clinician-based extension (p = 0.36), flexion (p = 0.076), and overall range of motion (p = 0.12).ConclusionPatients can self-assess their elbow range of motion following surgery for trauma accurately. In the midst of increasing demands for telemedicine, we suggest the application of patients' self-reporting outcome in clinical settings.     

Clinical outcome and determinants of amputation in a large cohort of Iranian patients with diabetic foot ulcers

ObjectiveDetermining the predictive factors of diabetes foot ulcer (DFU) development and lower extremity amputations (LEA) in patients with diabetes mellitus (DM) is of great importance to compose risk stratification models. The aim of this study is to investigate the outcome and predictors of LEA in patients with DFU in large sample of Iranian patients.MethodsThis prospective cohort study was conducted during a 2-year period from 2014 to 2016, in Shiraz, southern Iran. All the patients with type 1 and 2 DM and DFU were included in the cohort and were followed for 2 years at least. They were visited in the clinic on a monthly basis and development of new DFU and LEA were recorded. The two-year free-DFU survival and predictors of the DFU development and LEA were recorded. Multivariate regression models were used to determine the factors.ResultsA total number of 432 patients with mean age of 56.8 ± 13.3 years were included. The two-year DFU-free survival rate was 0.826. The two-year DFU-free survival was associated with male gender (p = 0.005), foot deformity (p = 0.002), history of prior DFU (p < 0.001), cigarette smoking (p = 0.032), nephropathy (p = 0.005), retinopathy (p = 0.007), ischemic heart disease (p = 0.043), and neuropathy (p < 0.001).ConclusionDevelopment of new DFU is associated with higher age, longer duration of disease, and type I diabetes. LEA was associated with increased white blood cell (WBC), Creatinine and ulcer history for major amputation and ulcer history, fasting blood sugar (FBS), infection, revascularization history, and foot deformity, for minor amputation.     

Glioblastoma in England: 2007–2011

AimsGlioblastoma (GBM) is the most common and aggressive primary malignant brain tumour in adults, with a poor prognosis. Changing treatment paradigms suggest improved outcome, but whole nation data for England is scarce. The aim of this report is to examine the incidence of patients with glioblastoma in England, and to assess the influence of gender, age, geographical region and treatment on outcome.MethodsA search strategy encompassing all patients coded with GBM and treated from January 2007 to December 2011 was obtained from data linkage between the National Cancer Registration Service and Hospital Episode Statistics for England.ResultsThere were 10,743 patients coded with GBM in this 5-year period (6451 male, 4292 female), giving an overall national age standardised incidence of 4.64/100,000/year. Incidence increases with age. Median survival overall was 6.1 months. One, 2 and 5-year survivals, were 28.4%, 11.5% and 3.4% respectively. Age stratified median survivals decreased significantly (p < 0.0001) with increasing age from 16.2 months for the 20–44 year age group, to 7.9 months for the 45–69 years, and 3.2 months for 70+ years. In the maximal treatment subgroup, patients aged up to 69 years had a median survival of 14.9 months. Patients over 60 years were less likely to receive maximal combination treatment but median survival was better with maximal treatment at all ages.ConclusionsThe overall outcome for patients with GBM remains poor. However, aggressive treatment at every age group is associated with extended survival similar to that described in clinical trials.